8-K: Sangamo Therapeutics Reports Q1 2024 Results and Pipeline Progress, Secures $24 Million in Funding

Sangamo Therapeutics announced its first quarter 2024 financial results, highlighted by a $49.1 million net loss, and provided updates on its neurology-focused pipeline and recent business developments, including a $24 million capital raise.

Summary

• Sangamo Therapeutics reported a net loss of $49.1 million for the first quarter of 2024, a significant decrease compared to a net income of $21.1 million in the same period of 2023.
• The company's revenue for the quarter was $0.5 million, a substantial drop from $158.0 million in the first quarter of 2023, primarily due to the termination of collaboration agreements with Biogen, Novartis, and the expiration of the Kite agreement.
• Operating expenses decreased to $52.0 million from $139.8 million year-over-year, with non-GAAP operating expenses at $43.6 million, down from $69.5 million in the prior year, due to cost-cutting measures.
• Sangamo raised approximately $24 million in gross proceeds through a registered direct offering with institutional investors.
• The company's cash and cash equivalents stood at $54.4 million as of March 31, 2024, down from $81.0 million at the end of 2023.
• Sangamo expects its current cash reserves, combined with cost savings, to fund operations into the third quarter of 2024.
• The company is advancing its neurology-focused pipeline, including the STAC-BBB capsid technology and the MINT platform for genome editing.
• The Phase 1/2 STAAR study for Fabry disease has completed dosing, and the company is actively seeking collaboration partners.
• Pfizer anticipates BLA and MAA submissions for the Hemophilia A program in early 2025, pending supportive pivotal readout in mid-2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and technology, the significant financial losses and reliance on future funding and partnerships temper the overall sentiment. The company's cash runway is also a concern.

Positives

• Sangamo has made significant progress in its neurology-focused pipeline, including the development of the STAC-BBB capsid and the MINT platform.
• The company successfully completed dosing in the Phase 1/2 STAAR study for Fabry disease.
• Sangamo is actively engaged in discussions with potential collaboration partners for its Fabry disease program and STAC-BBB technology.
• The company secured $24 million in funding through a direct offering, providing additional capital.
• Pfizer is progressing the Hemophilia A program with anticipated regulatory submissions in early 2025.
• The company has reduced operating expenses through restructuring and workforce reductions.

Negatives

• Sangamo reported a substantial net loss of $49.1 million for Q1 2024, a significant downturn from the previous year.
• Revenues decreased dramatically to $0.5 million due to the termination of key collaboration agreements.
• The company's cash reserves have decreased to $54.4 million, and they expect to be able to fund operations only into the third quarter of 2024.
• The company is deferring additional investments in the Fabry disease program until a collaboration or financing is secured.
• There is a reliance on potential milestone payments and royalties from the Hemophilia A program with Pfizer.

Risks

• Sangamo faces risks related to its lack of capital resources to fully develop and commercialize its product candidates.
• The company's ability to secure additional funding or partnerships is crucial for advancing its preclinical and clinical programs.
• There is a risk that preclinical results may not be indicative of results in future clinical trials.
• The company is subject to the uncertain and costly research and development process.
• Clinical trial delays, pauses, and holds could impact timelines and commercialization.
• The regulatory approval process for product candidates is unpredictable.
• There is a reliance on collaborators and the potential inability to secure additional collaborations.
• The company's financial guidance is subject to its ability to secure adequate additional funding.
• Macroeconomic factors and financial challenges could impact the company's operations and collaborations.

Future Outlook

Sangamo expects its current cash reserves, combined with cost savings, to fund operations into the third quarter of 2024. The company anticipates several milestones throughout the rest of 2024 and beyond, including IND and CTA submissions for its neurology programs, and potential regulatory submissions for the Hemophilia A program in early 2025. The company is also actively seeking partnerships for its Fabry disease program and other technologies.

Management Comments

• Sandy Macrae, Chief Executive Officer of Sangamo, stated that the company continues to progress its neurology-focused genomic medicine pipeline.
• Macrae also mentioned that the company is pleased with the progress being made in business development discussions across its portfolio, including the Fabry disease program.
• Macrae noted that the company is building on the momentum achieved in the first quarter and looks forward to achieving meaningful potential milestones throughout the rest of 2024 and beyond.

Industry Context

Sangamo's focus on genomic medicines, particularly in neurology, aligns with the growing interest in gene therapies and advanced delivery technologies. The development of novel capsids like STAC-BBB and genome editing platforms like MINT positions Sangamo as a key player in the field. The company's partnerships, such as the one with Pfizer for Hemophilia A, reflect the industry trend of collaboration to advance complex therapies. However, the financial challenges faced by Sangamo highlight the capital-intensive nature of drug development and the importance of securing funding and partnerships.

Comparison to Industry Standards

• Sangamo's STAC-BBB capsid technology is presented as having industry-leading blood-brain barrier penetration in non-human primates, which is a significant advancement compared to existing delivery methods.
• The MINT platform for large-scale genome editing is a novel approach that could differentiate Sangamo from companies using traditional CRISPR or other gene editing technologies.
• The completion of dosing in the Phase 1/2 STAAR study for Fabry disease is a positive step, but the company's decision to defer further investment until a partnership is secured is a common strategy for smaller biotech companies facing financial constraints.
• The anticipated BLA and MAA submissions for the Hemophilia A program with Pfizer are in line with the timelines of other gene therapy programs in late-stage development.
• The significant decrease in revenue and the net loss reported by Sangamo are not uncommon for biotech companies in the early stages of clinical development, but the magnitude of the revenue drop is notable and highlights the impact of terminated collaborations.
• Companies like BioMarin, which has a commercialized gene therapy for Hemophilia A, and uniQure, which focuses on gene therapies for neurological diseases, are key competitors in the space. Sangamo's success will depend on its ability to differentiate its technologies and secure partnerships.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and the decrease in cash reserves.
• Employees may be affected by the ongoing restructuring and workforce reductions.
• Patients with neurological diseases may benefit from the advancements in Sangamo's pipeline.
• Potential collaborators and partners are impacted by the company's need for funding and partnerships.
• Creditors are impacted by the company's financial situation and its ability to meet its obligations.

Next Steps

• Sangamo plans to participate in several investor conferences in May and June 2024.
• The company expects a pivotal readout from the Phase 3 AFFINE trial for Hemophilia A in mid-2024.
• IND submission is expected for the Nav1.7 program in Q4 2024.
• CTA submission is expected for the prion disease program in Q4 2025.
• The company intends to resume development of the zinc finger repressor program for tauopathies, with a potential IND submission as early as Q4 2025.
• Sangamo will continue to seek collaboration partners for its Fabry disease program and other technologies.
• The company will continue to monitor its cash position and seek additional funding as needed.

Key Dates

Keywords

Genomic Medicine, Gene Therapy, Neurology, Epigenetic Regulation, AAV Capsid, STAC-BBB, MINT Platform, Fabry Disease, Hemophilia A, Clinical Trials, Biotechnology, Financial Results